Rigel Pharmaceuticals Inc SEC filings RIGL
Rigel Pharmaceuticals Inc has 1,002 filings in SEC EDGAR's recent list, going back to Nov 6, 2007. Its latest annual report, Form 10-K, was filed on Mar 3, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 3, 2026 | — |
| DEF 14A | Proxy statement | Apr 3, 2026 | May 14, 2026 |
| DEFA14A | Additional proxy material | Apr 10, 2025 | — |
| DEF 14A | Proxy statement | Apr 10, 2025 | May 22, 2025 |
| DEFA14A | Additional proxy material | Apr 10, 2024 | — |
| DEF 14A | Proxy statement | Apr 10, 2024 | May 22, 2024 |
| PRE 14A | Preliminary proxy statement | Mar 29, 2024 | May 22, 2024 |
| DEFA14A | Additional proxy material | Apr 14, 2023 | — |
| DEF 14A | Proxy statement | Apr 14, 2023 | — |
| DEFA14A | Additional proxy material | Apr 5, 2022 | — |
| DEF 14A | Proxy statement | Apr 5, 2022 | May 19, 2022 |
| DEF 14A | Proxy statement | Apr 6, 2021 | May 18, 2021 |
| DEFA14A | Additional proxy material | May 1, 2020 | — |
| DEFA14A | Additional proxy material | Apr 1, 2020 | — |
| DEF 14A | Proxy statement | Apr 1, 2020 | May 14, 2020 |
| DEFA14A | Additional proxy material | Apr 9, 2019 | — |
| DEF 14A | Proxy statement | Apr 9, 2019 | May 22, 2019 |
| DEFA14A | Additional proxy material | Apr 4, 2018 | — |
| DEF 14A | Proxy statement | Apr 4, 2018 | May 16, 2018 |
| PRE 14A | Preliminary proxy statement | Mar 23, 2018 | May 16, 2018 |
| DEFA14A | Additional proxy material | Mar 29, 2017 | — |
| DEF 14A | Proxy statement | Mar 29, 2017 | Mar 29, 2017 |
| DEFA14A | Additional proxy material | May 3, 2016 | — |
| DEFA14A | Additional proxy material | Mar 28, 2016 | — |
| DEF 14A | Proxy statement | Mar 28, 2016 | May 10, 2016 |
| DEFA14A | Additional proxy material | Mar 30, 2015 | — |
| DEF 14A | Proxy statement | Mar 30, 2015 | May 12, 2015 |
| DEF 14A | Proxy statement | Apr 8, 2014 | May 20, 2014 |
| DEFA14A | Additional proxy material | Apr 8, 2014 | — |
| DEFA14A | Additional proxy material | Apr 3, 2013 | — |
| DEF 14A | Proxy statement | Apr 3, 2013 | May 14, 2013 |
| DEFA14A | Additional proxy material | Apr 12, 2012 | — |
| DEF 14A | Proxy statement | Apr 12, 2012 | May 22, 2012 |
| PRE 14A | Preliminary proxy statement | Mar 30, 2012 | May 22, 2012 |
| DEFA14A | Additional proxy material | Apr 4, 2011 | — |
| DEF 14A | Proxy statement | Apr 4, 2011 | May 19, 2011 |
| DEFA14A | Additional proxy material | Apr 12, 2010 | — |
| DEF 14A | Proxy statement | Apr 12, 2010 | May 27, 2010 |
| DEFA14A | Additional proxy material | Apr 15, 2009 | — |
| DEF 14A | Proxy statement | Apr 15, 2009 | May 28, 2009 |
| DEF 14A | Proxy statement | Apr 8, 2008 | May 29, 2008 |
Showing 41 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RIGL (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- Accelerated filer
- SEC CIK
- 1034842
- Former names
- RIGEL PHARMACEUTICALS INC (until Nov 5, 2026)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.